CRINETICS PHARMACEUTICALS, INC. 7,576,000 Shares of Common Stock, par value $0.001 per share Underwriting AgreementCrinetics Pharmaceuticals, Inc. • October 21st, 2021 • Pharmaceutical preparations • New York
Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 7,576,000 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Firm Shares”) and, at the election of the Underwriters, up to 1,136,400 additional shares (the “Optional Shares”) of Common Stock of the Company. The Firm Shares and Optional Shares that the Underwriters elect to purchase are collectively referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. For purposes of this underwriting agreement (this “Agreement”), the term Representatives as used herein shall mean SVB Leerink LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co.
